Para o público jovem, de 12 a 17 anos, haverá a antecipação da 2ª dose da Pfizer de 12 para 8 semanas (há estratégia programada para este público na terça-feira, 26). Para a população de 18 anos ou mais, haverá a antecipação da 2ª dose de 8 semanas para 21 dias (tem estratégia programada para este público na segunda-feira, 25).

NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their mRNA-based combination vaccine candidate for influenza and COVID-19, which aims to help prevent two respiratory diseases with a single injection. SAN FRANCISCO (KGO) -- Over the past few weeks, California has rapidly expanded its vaccine eligibility, meaning millions of people are getting a dose of the COVID-19 vaccine for the first time
Bivalent vaccine authorized as third 3-µg dose in the three-dose primary series Consistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among children under 5 in the United States creates urgent need to make updated COVID-19 vaccines available Doses to ship immediately upon recommendation by CDC Pfizer Inc. (NYSE: PFE) and BioNTech SE

The first U.S. multisite test-negative design vaccine effectiveness study among HCP found a single dose of Pfizer-BioNTech or Moderna COVID-19 vaccines to be 82% effective against symptomatic COVID-19 and 2 doses to be 94% effective.

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 Ashley L. Fowlkes, ScD. 1; Sarang K. Yoon, DO. 2; Karen Lutrick, PhD. 3; Lisa Gwynn, DO. 4; Joy Burns, PhD. 5; Lauren Grant, MS. 1 Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios for Omicron neutralizing antibody response consistent with regulatory requirement of superiority Positive pivotal top-line data demonstrates 20-valent pneumococcal conjugate vaccine candidate (20vPnC), if approved, can likely help protect against all 20 vaccine serotypes in three-dose series and potentially offer the broadest serotype coverage of any available pneumococcal conjugate vaccine (PCV) The safety profile of 20vPnC was favorable and similar to Prevenar 13® (or Prevnar 13® in
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food and Drug Administration (FDA) has approved STEGLATROâ„¢(ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJANâ„¢ (ertugliflozin and sitagliptin) tablets.
Results previously published in the Journal of the American Medical Association Network Open from the Phase 2 study (NCT03985293) of danuglipron in type 2 diabetes showed dose-dependent placebo-adjusted reductions in HbA1c of up to -1.16%; fasting plasma glucose of -33.24 mg/dL; and body weight of -4.17 kg over 16 weeks.
Entenda a antecipação da 2ª dose da Pfizer e da AstraZeneca em Aracaju; 02/08/2021 - 14H46 Balanço Geral Sergipe
.
  • 28jcouhtwl.pages.dev/42
  • 28jcouhtwl.pages.dev/74

    • antecipacao 2 dose pfizer